Assessment of Clinical Trial Experiences of Alzheimer's Disease Patients
NCT05672732 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-06-18
Summary
Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
This study will admit a wide range of data on the clinical trial experience of Alzheimer's Disease patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Alzheimer's Disease patients.
Conditions
- Alzheimer Disease
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 50 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-02-29
- Primary Completion
- 2025-02-28
- Completion
- 2026-02-28
More Related Trials
-
Memory Aid for Informed Consent in Alzheimer's Research
NCT00105612 ·Status: COMPLETED ·Phase: NA
-
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
NCT02907567 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
NCT03462121 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709 ·Status: RECRUITING ·Phase: PHASE2
-
The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia
NCT02187276 ·Status: COMPLETED
-
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
NCT00874939 ·Status: TERMINATED ·Phase: PHASE1
-
Characteristics of Treatment Responders to Galantamine
NCT01029132 ·Status: COMPLETED ·Phase: NA
-
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
NCT01054976 ·Status: COMPLETED ·Phase: PHASE4
-
The Evaluation and Follow-up of Individuals With Memory Disorder
NCT00001480 ·Status: COMPLETED
-
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease
NCT01921972 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Research of Alzheimer's Disease Drugs
NCT01362686 ·Status: TERMINATED ·Phase: NA
-
Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease
NCT03363269 ·Status: COMPLETED ·Phase: PHASE2
-
Gene-Environment Interactions in Alzheimer's Disease
NCT00018473 ·Status: COMPLETED
-
Treatment of Language and Memory in Patients With Alzheimer's Disease
NCT00593372 ·Status: COMPLETED ·Phase: PHASE1
-
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
NCT00842673 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
NCT01807026 ·Status: COMPLETED ·Phase: PHASE1
-
Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
NCT00955422 ·Status: COMPLETED
-
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
NCT05771428 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
NCT05363293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
NCT00236431 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Magnetic Fields to Treat Alzheimer's Disease
NCT01313806 ·Status: WITHDRAWN ·Phase: NA
-
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
NCT02097056 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
NCT02626572 ·Status: COMPLETED ·Phase: PHASE2
-
A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia
NCT00035191 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period
NCT00299676 ·Status: COMPLETED